These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30400617)

  • 1. Preclinical Pharmacokinetics of C118P, a Novel Prodrug of Microtubules Inhibitor and Its Metabolite C118 in Mice, Rats, and Dogs.
    Zhang C; Zhang X; Wang G; Peng Y; Zhang X; Wu H; Yu B; Sun J
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30400617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.
    Yang M; Su Y; Wang Z; Du D; Wei S; Liao Z; Zhang Q; Zhao L; Zhang X; Han L; Jiang J; Zhan M; Sun L; Yuan S; Zhou Z
    Biochem Pharmacol; 2021 Aug; 190():114641. PubMed ID: 34077738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.
    Hu ZY; Li XX; Du FF; Yang JL; Niu W; Xu F; Wang FQ; Li C; Sun Y
    Acta Pharmacol Sin; 2013 Nov; 34(11):1437-48. PubMed ID: 24056706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs.
    Dash RP; Tichý T; Veeravalli V; Lam J; Alt J; Wu Y; Tenora L; Majer P; Slusher BS; Rais R
    Mol Pharm; 2019 Oct; 16(10):4292-4301. PubMed ID: 31503493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
    Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles.
    Li CM; Lu Y; Narayanan R; Miller DD; Dalton JT
    Drug Metab Dispos; 2010 Nov; 38(11):2032-9. PubMed ID: 20675405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
    Ong V; Flanagan S; Fang E; Dreskin HJ; Locke JB; Bartizal K; Prokocimer P
    Drug Metab Dispos; 2014 Aug; 42(8):1275-84. PubMed ID: 24875463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174.
    Yan YD; Kim HK; Seo KH; Lee WS; Lee GS; Woo JS; Yong CS; Choi HG
    Mol Pharm; 2010 Dec; 7(6):2132-40. PubMed ID: 20849146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer.
    Yang J; Ahn S; Wu Z; Hwang DJ; Miller DD; Dalton JT
    Int J Oncol; 2012 Jul; 41(1):337-44. PubMed ID: 22576690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor.
    Li N; Qiu Z; Wang X; Li T; Ji H; Zhang Y; Lu Y; Zhao D; Chen X
    Xenobiotica; 2014 Jan; 44(1):59-69. PubMed ID: 23773000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist.
    Fujitaki JM; Cable EE; Ito BR; Zhang BH; Hou J; Yang C; Bullough DA; Ferrero JL; van Poelje PD; Linemeyer DL; Erion MD
    Drug Metab Dispos; 2008 Nov; 36(11):2393-403. PubMed ID: 18703645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
    Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
    Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
    Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.